3-Azidopropanoyl 3-azidopropanoate | 1221559-84-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-Azidopropanoyl 3-azidopropanoate
• CAS: 1221559-84-7
• 化学式: C₆H₈N₆O₃
• 分子量: 212.168
• InChiKey: WBYQSYNCZDSCIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-Azidopropanoyl 3-azidopropanoate 、 辅酶 A 在 盐酸 作用下， 以 水 、 乙腈 为溶剂， 生成 3-azidopropanoyl CoA
  参考文献：
  名称：

  Labeling Lysine Acetyltransferase Substrates with Engineered Enzymes and Functionalized Cofactor Surrogates

  摘要：

  Elucidating biological and pathological functions of protein lysine acetyltransferases (KATs) greatly depends on the knowledge of the dynamic and, spatial localization of their enzymatic targets in the cellular proteome. We report the design and application of chemical probes for facile labeling and detection of substrates of the three major human KAT enzymes. In this approach, we create engineered KATs in junction with synthetic Ac-CoA surrogates to effectively label KAT, substrates even in the presence of competitive nascent cofactor acetyl-CoA. The functionalized and transferable acyl moiety of the Ac-CoA analogs further allowed the labeled substrates to be probed with alkynyl or azido-tagged fluorescent reporters by the copper-catalyzed azide-alkyne cycloaddition. The synthetic cofactors, in combination with either native or rationally engineered KAT enzymes, provide a versatile chemical biology strategy to label and profile cellular targets of KATs at the proteomic level.

  DOI：

  10.1021/ja311636b
• 作为产物：
  描述：

  3-叠氮丙酸 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 3-Azidopropanoyl 3-azidopropanoate
  参考文献：
  名称：

  Labeling Lysine Acetyltransferase Substrates with Engineered Enzymes and Functionalized Cofactor Surrogates

  摘要：

  Elucidating biological and pathological functions of protein lysine acetyltransferases (KATs) greatly depends on the knowledge of the dynamic and, spatial localization of their enzymatic targets in the cellular proteome. We report the design and application of chemical probes for facile labeling and detection of substrates of the three major human KAT enzymes. In this approach, we create engineered KATs in junction with synthetic Ac-CoA surrogates to effectively label KAT, substrates even in the presence of competitive nascent cofactor acetyl-CoA. The functionalized and transferable acyl moiety of the Ac-CoA analogs further allowed the labeled substrates to be probed with alkynyl or azido-tagged fluorescent reporters by the copper-catalyzed azide-alkyne cycloaddition. The synthetic cofactors, in combination with either native or rationally engineered KAT enzymes, provide a versatile chemical biology strategy to label and profile cellular targets of KATs at the proteomic level.

  DOI：

  10.1021/ja311636b

文献信息

• [EN] SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY<br/>[FR] ANTAGONISTES DE LA SÉLECTINE OU DE LA GALECTINE POUR LE TRAITEMENT DU SYNDROME DE LIBÉRATION DE LA CYTOKINE ET DE LA NEUROTOXICITÉ INDUITE PAR LE CRS
  申请人：MAGNANI JOHN L

  公开号：WO2020150263A1

  公开（公告）日：2020-07-23

  Methods and compounds for the treatment and/or prevention of CRS and/or CRS-induced neurotoxicities using at least one selectin antagonist are disclosed. The disclosed methods and compounds use at least one of the disclosed antagonists to target and reduce cytokine expression and/or endothelial activation to treat and/or prevent CRS and/or CRS-related conditions such as CRS-induced neurotoxicities.

  使用至少一种选择素拮抗剂治疗和/或预防CRS和/或CRS诱导的神经毒性的方法和化合物被披露。披露的方法和化合物使用至少一种披露的拮抗剂来靶向和减少细胞因子表达和/或内皮活化，以治疗和/或预防CRS和/或CRS相关症状，如CRS诱导的神经毒性。
• [EN] GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS<br/>[FR] INHIBITEURS GLYCOMIMÉTIQUES MULTIMÈRES LIÉS AU GALACTOSE DE SÉLECTINES E, DE GALECTINE-3 ET/OU DE RÉCEPTEURS DE CHIMIOKINE CXCR4
  申请人：GLYCOMIMETICS INC

  公开号：WO2020219417A1

  公开（公告）日：2020-10-29

  Compounds, compositions, and methods for treating and/or preventing at least one disease, disorder, and/or condition associated with E-selectin, galectin-3, and/or CXCR4 chemokine receptor activity are disclosed herein. For example, multimeric glycomimetic inhibitors ofE-selectins, galectin-3, and/or CXCR4 chemokine receptors and their use for treating and/or preventing inflammatory diseases, fibrosis, and cancers are disclosed. Formula (I).

  本文揭示了用于治疗和/或预防与E-选择素、galectin-3和/或CXCR4趋化因子受体活性相关的至少一种疾病、紊乱和/或状况的化合物、组合物和方法。例如，本文揭示了用于治疗和/或预防炎症性疾病、纤维化和癌症的E-选择素、galectin-3和/或CXCR4趋化因子受体的多聚糖类似物抑制剂及其用途。公式（I）。
• METHODS OF TREATING HIV AND AIDS AND THE ELIMINATION OF LATENT RESERVOIRS OF HIV INFECTION USING SELECTIN, GALECTIN, AND SIGLEC ANTAGONISTS
  申请人：GlycoMimetics, Inc.

  公开号：EP3893936A2

  公开（公告）日：2021-10-20
• SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY
  申请人：GlycoMimetics, Inc.

  公开号：EP3911307A1

  公开（公告）日：2021-11-24
• METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES
  申请人：GlycoMimetics, Inc.

  公开号：EP3997247A1

  公开（公告）日：2022-05-18